Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause S, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 136

Pages Range: 823-830

Journal Issue: 7

DOI: 10.1182/blood.2019004583

Abstract

In fit patients with newly diagnosed acute myeloid leukemia (AML), immediate treatment start is recommended due to the poor prognosis of untreated acute leukemia. We explored the relationship between time from diagnosis to treatment start (TDT) and prognosis in a large real-world data set from the German Study Alliance Leukemia-Acute Myeloid Leukemia (SAL-AML) registry. All registered non-acute promyelocytic leukemia patients with intensive induction treatment and a minimum 12 months of follow-up were selected (n = 2263). We analyzed influence of TDT on remission, early death, and overall survival (OS) in univariable analyses for each day of treatment delay, in groups of 0 to 5, 6 to 10, 11 to 15, and >15 days of TDT, adjusted for influence of established prognostic variables on outcomes. Median TDT was 3 days (interquartile range, 2-7). Unadjusted 2-year OS rates, stratified by TDT of 0 to 5, 6 to 10, 11 to 15, and >15 days, were 51%, 48%, 44%, and 50% (P = .211). In multivariable Cox regression analysis accounting for established prognostic variables, the TDT hazard ratio as a continuous variable was 1.00 (P = .617). In OS analyses, separately stratified for age ≤60 and >60 years and for high vs lower initial white blood cell count, no significant differences between TDT groups were observed. Our study suggests that TDT is not related to survival. As stratification in intensive first-line AML treatment evolves, TDT data suggest that it may be a feasible approach to wait for genetic and other laboratory test results so that clinically stable patients are assigned the best available treatment option. This trial was registered at www.clinicaltrials.gov as #NCT03188874.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Jena Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Münster Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Rems-Murr-Kliniken Germany (DE) Klinikum Chemnitz Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Universitätsklinikum Essen Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE) Klinikum Bielefeld Germany (DE) Universitätsklinikum Würzburg Germany (DE) St. Bernward Krankenhaus Germany (DE) Robert-Bosch-Krankenhaus Germany (DE) Klinikum Bayreuth Germany (DE) Horst-Schmidt-Kliniken Germany (DE) Universitätsklinikum Leipzig Germany (DE) Universitätsklinikum Halle (Saale) Germany (DE)

How to cite

APA:

Röllig, C., Kramer, M., Schliemann, C., Mikesch, J.H., Steffen, B., Krämer, A.,... Bornhäuser, M. (2020). Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood, 136(7), 823-830. https://doi.org/10.1182/blood.2019004583

MLA:

Röllig, Christoph, et al. "Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?" Blood 136.7 (2020): 823-830.

BibTeX: Download